Prognostic value of c-Met overexpression in hepatocellular carcinoma: a meta-analysis and review
Metrics: PDF 1354 views | HTML 2348 views | ?
Jung Han Kim1, Hyeong Su Kim1, Bum Jun Kim1,3, Hyun Joo Jang2 and Jin Lee2
1Division of Hemato-Oncology, Department of Internal Medicine, Kangnam Sacred-Heart Hospital, Hallym University Medical Center, Hallym University College of Medicine, Seoul 07441, Republic of Korea
2Division of Gastroenterology, Department of Internal Medicine, Dongtan Sacred-Heart Hospital, Hallym University Medical Center, Hallym University College of Medicine, Hwasung 18450, Republic of Korea
3Department of Internal Medicine, National Army Capital Hospital, The Armed Forces Medical Command, Sungnam 13574, Republic of Korea
Jung Han Kim, email: [email protected]
Hyun Joo Jang, email: [email protected]
Keywords: c-Met, hepatocellular carcinoma, prognostic value, meta-analysis
Received: June 08, 2017 Accepted: July 26, 2017 Published: August 09, 2017
The overexpression of c-Met protein has been detected in hepatocellular carcinoma (HCC). However, its prognostic impact remains uncertain. We performed this meta-analysis to evaluate the prognostic value of c-Met overexpression in patients who underwent curative surgical resection for HCC. A systematic computerized search of the electronic databases was carried out. From 5 studies, 1,408 patients who underwent surgical resection for HCC were included in the meta-analysis. Compared with patients with HCC having low c-Met expression, patients with c-Met-high tumor showed significantly worse relapse-free survival (hazard ratio = 1.26 [95% confidence interval, 1.02–1.56], P = 0.03) and overall survival (hazard ratio = 1.16 [95% confidence interval, 1.03–1.31], P = 0.01). In conclusion, our meta-analysis indicates that c-Met overexpression is a significant adverse prognostic factor for recurrence and survival in patients who underwent surgical resection for HCC.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.